An update on TAK-861 and orexin agonists in narcolepsy type 1

Emmanuel Mignot, MD, PhD, Stanford University School of Medicine, Palo Alto, CA, discusses TAK-861, an investigational oral orexin receptor 2 agonist, which has recently entered into Phase III clinical studies for narcolepsy type 1 (NT1) (NCT06470828). This comes as a result of positive Phase IIb clinical data presented earlier this year, whereby TAK-861 demonstrated statistically significant and clinically meaningful increased sleep latency on the Maintenance of Wakefulness Test (MWT). The drug had similarly been investigated in NT2 (NCT05687916); however, it was not found to be efficacious in this population, likely due to differences in the orexin pathology between NT1 and NT2. This interview took place at the Sleep Europe 2024 congress in Seville, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.